DENVER, Dec. 10, 2010 (GLOBE NEWSWIRE) -- MusclePharm® Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, today announced it has reached an agreement to raise $1.4 million through a convertible promissory note and registration agreement with an accredited investor.
"We are very pleased with the successful completion of the agreement with the investor and believe this capital will support our capital requirements for growth," commented Brad Pyatt, MusclePharm's Chief Executive Officer. "We appreciate our investor's confidence in MusclePharm as we continue to execute our long-term growth strategy."
This capital raise, combined with the previously released fulfillment agreement with IVitals, further enhances the Company's overall financial strength for future long-term profitable growth. Management will continue to focus on the development, sales & marketing of MusclePharm's growing portfolio of nutritional supplement products.
About MusclePharm®
Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufactures a full line of NSF and scientifically approved, nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company's propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 US retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com. For more information, please visit www.musclepharm.com.
Forward-looking Statements
MusclePharm Corporation believes the information set forth in this Press Release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in "Risk Factors" in Item 2.02 of the Company's Form 8-K dated February 18, 2010, which has been filed with the Securities and Exchange Commission.